Treatment News : Universal HIV Therapy Supresses Viral Loads in Those With CD4s Above 500

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » December 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


December 11, 2012

Universal HIV Therapy Supresses Viral Loads in Those With CD4s Above 500

Universally recommending HIV therapy significantly increases the likelihood of viral suppression among those with CD4 counts above 500, according to a new study. Researchers from the Division of HIV/AIDS at San Francisco General Hospital (SFGH) and other groups from San Francisco evaluated the effect of the hospital’s January 1, 2010, policy shift to advise universal use of antiretrovirals (ARVs) regardless of CD4 counts. They published their findings in Clinical Infectious Diseases.

The researchers examined a cohort of untreated HIV-positive adults with CD4 counts above 500 who, between January 1, 2001, and November 1, 2011, made at least one visit to the SFGH’s Ward 86 clinic. The clinic is a “safety net” health care provider that serves a largely indigent population with a high proportion of homelessness, substance abuse and psychiatric conditions. The scientists broke up their data into eras defined by evolving recommendations about when to start HIV treatment and then observed the percentage of each cohort that reached an undetectable viral load within one year after starting treatment.

Between January 1, 2001, and April 4, 2005, when the United States Department of Health and Human Services (HHS) advised against starting therapy when CD4 cells are above 500, 10.1 percent of the cohort reached viral suppression. Between April 5, 2005, and December 1, 2007, which had the same guidelines and served as a control group to evaluate trends unrelated to the treatment guidelines, the suppressed percentage was 9.1 percent. Between December 2, 2007, and January 1, 2010, when HHS changed its policy in regards to starting treatment when CD4 counts are above 500 from “not recommended” to “optional,” the percentage rose to 14.1 percent. From January 2010 to the end of 2010, after the change in SFGH’s treatment policy, the percentage jumped to 52.8 percent.

To read the study abstract, click here.

Search: HIV, universal therapy, viral suppression, CD4 counts above 500, Division of HIV/AIDS, San Francisco General Hospital, SFGH, antiretrovirals, ARVs, Ward 86 clinic, homelessness, substance abuse, psychiatric conditions, recommendations, treatment guidelines.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.